PSYCHEDELICS CANADA ANNOUNCES THE LAUNCH OF THE FIRST NATIONAL TRADE ASSOCIATION FOR LEGAL PSYCHEDELICS COMPANIES

PSYCHEDELICS CANADA TO FOCUS ON IMPROVING THE REGULATORY ENVIRONMENT FOR MEDICAL RESEARCH IN PSYCHEDELICS

TORONTO, ON – May 27, 2022 – (Canada Newswire) 12 companies from across the country joined forces today to found Psychedelics Canada, the first, national-level trade association representing the blossoming psychedelic medicine and therapy industry. Incorporated as a not-for-profit trade association, Psychedelics Canada speaks on behalf of the legal psychedelics industry to government, the press, and the public. The launch of the association in Toronto coincides with From Research to Reality: The Global Summit on Psychedelic-Assisted Therapies and Medicine.

“There has been so much interest in the healing properties of psychedelic molecules over the past few years. Unfortunately, governments have not had a single trusted interlocutor which represents the legal psychedelics industry,” said Nick Kadysh, CEO of PharmAla Biotech, and Board Chair of Psychedelics Canada. “I believe that the formation of this association will change that. Already, the companies behind Psychedelics Canada are working together, as a cluster, to advance the research and development of psychedelic molecules.”

The founding members of Psychedelics Canada include:

• Absolem Health
• PharmAla Biotech
• Psygen
• Filament Health
• Bloom Psychedelics
• Pharmather
• SABI Mind
• 5D World
• Cybin
• Psyched Wellness
• EntheoTech
• spark*advocacy

“Today’s announcement is a historic milestone for the development of the psychedelics industry – the first national-level trade association for psychedelics companies anywhere in the world,” said Liam Bedard, Coordinator of Psychedelics Canada.

We are here to champion the benefits of science-based, psychedelic therapies administered by qualified practitioners to Canadians suffering from a range of physical and mental health conditions. I urge all members of the legal, regulated psychedelics industry to join us in tackling the urgent priorities of mental health, scientific discovery, and government regulation that we all share.”

 

-30-